ライフサイエンスコーパス: complement factor

1 rafiltrate-derived serum proteins, including complement factors.

2 gated specific interactions between IAPP and complement factors.

3 itors alpha(2)-macroglobulins and vertebrate complement factors.

4 anaphylotoxin domain, a central component of complement factors.

5 ibition or from increased local synthesis of complement factors.

6 ) is impaired, despite elevations of certain complement factors.

7 t attachment analogous to that used by human complement factors.

8 human-inflamed tissue and allows binding of complement factor 1q (C1q) and activation of the classic

9 ient (C1q KO), MBL-A/C-deficient (MBL-null), complement factor 2- and factor B-deficient (C2/fB KO),

10 Complement factor 3 (C3) deficiency causes prolonged ble

11 expression construct in which (1) the murine complement factor 3 (C3) promoter regulates production o

12 platelet counts and lower concentrations of complement factor 3 and blood urea nitrogen but higher s

13 significantly more opsonized with activated complement factor 3 and membrane attack complex from ser

14 in a very potent downregulation of activated complement factor 3 opsonization on the pathogen surface

15 We identify a nonsynonymous coding change in complement factor 3 that is strongly associated with ris

16 more importantly it also captures activated complement factor 3 within the complex with factor B, th

17 were interferon-stimulated growth factor-3, complement factor 3, nicotinamide N-methyltransferase, m

18 eport that amyloid clearance in mice lacking complement factors 3 and 4 (C3C4(-/-)) was equally effic

19 eficient in mannose-binding lectin (Mbl2) or complement factor 3a receptor (C3aR).

20 thway involved, we studied mice deficient in complement factor 4 (C4-/-), a critical component of the

21 Complement factor 5 (C5) and its cleavage product C5a ar

22 us analysis, we identified the gene encoding complement factor 5 (C5) as a susceptibility locus for a

23 Here, we report that complement factor 5 (C5) contributes significantly to ch

24 naphylatoxins, as mouse strains deficient in complement factor 5 (C5) or the complement receptor C5aR

25 e to a defect in the Hc locus, which encodes complement factor 5 (C5).

26 Complement factor 5a (C5a) is an anaphylatoxin that acts

27 peptidic ligands is the chemotactic cytokine complement factor 5a (C5a), a 74-amino acid helical bund

28 he ligand binding pocket in the receptor for complement factor 5a (C5aR), we assessed binding affinit

29 novel EC3-N terminus cysteine pair into the complement factor 5a receptor (C5aR), a chemo attractant

30 tial residues in the N terminus of the human complement factor 5a receptor (C5aR).

31 Complement factor 9 (C9) gene was localized next to the

32 generated postvaccination were recognized by complement factors and assisted in killing S.

33 on of dysferlin normalized the expression of complement factors and eliminated the dystrophic phenoty

34 BPI release is probably mediated by non-complement factors and may be related to the nutritional

35 Notably, complement factors and their fragments may serve as biom

36 ituations such as protease regulators (e.g., complement factors and trypsin inhibitors) and intracell

37 in (apoJ), PLTP itself, coagulation factors, complement factors, and apoA-I.

38 Most strikingly, complement factors appear to be involved in limb regener

39 Hence, antibodies or complement factors are not necessary for natural amyloid

40 apoptotic cells activate complement and some complement factors are opsonins for phagocytosis and pla

41 Complement factors are serum proteins that work through

42 s with Y225 (like some blood coagulation and complement factors) are almost exclusively found in vert

43 assays utilizing sera depleted of individual complement factors as well as adding back purified facto

44 he association of complement component 2(C2)/complement factor B (CFB) gene polymorphisms with age-re

45 ariants in the complement factor H (CFH) and complement factor B (CFB) genes has targeted the search

46 crosis factor alpha (TNF-alpha) induction of complement factor B (CFB) in RPE cells.

47 ned the roles of complement component C3 and complement factor B (CFB) in the growth of cSCC.

48 Complement factor B (cfB) is an essential component of t

49 on of TLR2, TLR3, and TLR4 markedly enhanced complement factor B (cfB) synthesis and release by macro

50 (ARMS2/HTRA1), complement component 2 (C2), complement factor B (CFB), complement component 3 (C3),

51 We studied 1 of these proinflammatory genes, complement factor B (Cfb), in detail, because complement

52 th rs3736265 and a AMD-associated variant in complement factor B (CFB, rs512559).

53 nt 3 (rs2230199), and complement component 2/complement factor B (rs4151667) were examined using mult

54 e susceptibility to AOM in mice deficient in complement factor B and C2 (Bf/C2(-/)(-)), C1qa (C1qa(-/

55 hibitor impaired the interaction of C3b with complement factor B and, consequently, formation of the

56 on mutation in mice and a mutant form of the complement factor B protein that produces a stable, prop

57 We derived complement factor B wild-type (B+/+), homozygous knockou

58 x 10(-47)), C2 (complement component 2)-CFB (complement factor B) (P =5.2 x 10(-9)), C3 (complement c

59 ternative pathway and that mice deficient in complement factor B, an essential component of the alter

60 of mRNAs for CD3epsilon, CD105, TLR4, CD14, complement factor B, and vimentin that distinguishes acu

61 plement component 2, complement component 3, complement factor B, collagen type VIII alpha 1, and RAD

62 c alpha-2 glycoprotein, alpha-1 antitrypsin, complement factor B, haptoglobin, transthyretin, plasma

63 chitinase 3-like protein 1 (CHI3L1), CHI3L2, complement factor B, matrix metalloproteinase 3, ECM-1,

64 ucing a second mutation in the gene encoding complement factor B, which prevents C3 turnover in vivo,

65 the alternative pathway in lupus nephritis, complement factor B-deficient mice were backcrossed to M

66 ibrinogen, haptoglobin, serum amyloid A, and complement factors (B, C3, and C9).

67 virions in body fluids can be opsonized with complement factors because of HIV-mediated triggering of

68 Flow cytometry assays were used to assess complement factor binding and complement-dependent neutr

69 subsets is severely hampered in mice lacking complement factor C1q (C1qa(-/-)).

70 ovel approach could also be applied to other complement factor C1q family members; in particular, thi

71 g up-regulation of synapse pruning-promoting complement factor C1q, and down-regulation of Etv1/ER81,

72 shares significant homology with subunits of complement factor C1q, collagen alpha 1(X), and the brai

73 lecules, such as the classical FcgammaRs and complement factor C1q, has not been studied in detail.

74 binding to both the classical FcgammaRs and complement factor C1q, which ultimately results in alter

75 ating the expression levels of VEGFD and the complement factor C1q-c, two nuclear calcium-regulated g

76 nediaminetetraacetic acid-treated normal and complement factors C1q, C4/C3, C2, C3, factor B or C5-de

77 microinjection data are consistent with the complement factor C2/B-like model.

78 that it is structurally similar to mammalian complement factors C2 and B has been previously proposed

79 We evaluated the role of complement factor C3 (C3) and the murine gamma-herpesvir

80 inflammation-related factors common to TBI: complement factor C3 (C3), glial fibrillary acidic prote

81 e mode of action of the Ab did not depend on complement factor C3 and did not lead to improved Ag pre

82 plement receptors and upon serum with intact complement factor C3 and that uptake requires actin micr

83 t otherwise functional AHR mutant identified complement factor C3 as a potential SAhRM target.

84 t that the classical pathway is required for complement factor C3 deposition on the bacterial surface

85 otein factor H directly, thereby, preventing complement factor C3 deposition on the surface of the ba

86 Complement factor C3 is made in rheumatoid synovium and

87 Complement factor C3 is the central component of the com

88 We examine whether complement factor C3 or C5 is synthesized by human skin-

89 Here we show that the central complement factor C3 secreted from astrocytes interacts

90 s, the protective mAbs more efficiently bind complement factor C3 to the yeast cell than do nonprotec

91 which binds to extracellular fibrinogen and complement factor C3, might partially contribute to bact

92 rall protein fold of TEP1r resembles that of complement factor C3, the TEP1r domains are repositioned

93 erformed with antibodies detecting activated complement factor C3, transferrin receptor, L-ferritin,

94 rious collagens, nidogen, thrombospondin, or complement factors C3 and C3b.

95 rs of matrix metalloproteases (TIMPs) and in complement factors C3 and C5.

96 in the RPE, which significantly reduced the complement factors C3/C3b in the RPE.

97 Binding of complement factors C3b, IgM, C1q, mannose-binding lectin

98 mining the human leukocyte antigen (HLA) and complement factor C4 genes and proteins.

99 tivate complement as measured by cleavage of complement factor C4.

100 enes and the complex structural diversity of complement factor C4A/C4B It has also uncovered extensiv

101 determine the prevalence and localization of complement factor C4d in kidneys of patients with TMA.

102 induction therapy, gusperimus, belimumab and complement factor C5a inhibition are also ongoing, and m

103 Complement factor C5a slightly increases the expression

104 The chemotactic response to the complement factors C5a and C3a is ablated in cells lacki

105 cells (HUVECs) by real-time PCR: C3 and C5; complement factor (CF) B, CFD, CFP, CFH and CFI of the A

106 It had been thought that complement factor D (FD) is activated at the site of syn

107 Pretreatment plasma complement factor D concentrations also decreased with t

108 ion in the presence of eculizumab or control complement factor D inhibitor ACH-4471, which blocks the

109 eatinine) and large (ss(2)-microglobulin and complement factor D) solutes was significantly greater f

110 Validation of 4 PVAN-specific genes (RPS15, complement factor D, lactotransferrin, and nitric oxide

111 the structure of its mature serine protease, complement factor D, revealed major conformational chang

112 Analysis of complement factors does not reveal any changes that are

113 Ligands include the complement factor fragment iC3b, a key component in the

114 Genetic risk was based on Y402H in complement factor H (CFH) and A69S in age-related maculo

115 ants were genotyped for polymorphisms in the complement factor H (CFH) and age-related maculopathy su

116 Two biologically related factors, complement factor H (CFH) and C-reactive protein (CRP),

117 the relationship between local (ie, ocular) complement factor H (CFH) and choroidal neovascularizati

118 Association of variants in the complement factor H (CFH) and complement factor B (CFB)

119 tion cluster at chromosome 1q32 contains the complement factor H (CFH) and five complement factor H-r

120 s study, we investigated the associations of complement factor H (CFH) and hemicentin-1 (HMCN1) with

121 ctivation and genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD

122 In addition, to determine the regulation of complement factor H (CFH) by oxidative stress, in vitro

123 Genetic variations in complement factor H (CFH) confer greater risk for age-re

124 f this disease, identifying mutations in the complement factor H (CFH) gene and a locus on chromosome

125 Rare variants in the complement factor H (CFH) gene and their association wit

126 anding puzzle why non-coding variants in the complement factor H (CFH) gene are more strongly associa

127 Variations in the complement factor H (CFH) gene are tightly associated wi

128 S, with a focus on genetic variations in the complement Factor H (CFH) gene cluster and CFH autoantib

129 us carriers of the Y402H risk variant in the complement factor H (CFH) gene developed neovascular AMD

130 ransition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics e

131 ty variants and protective haplotypes in the complement factor H (CFH) gene modulate risk for AMD.

132 mparted by carrying the Y402H variant in the complement factor H (CFH) gene on chromosome 1, recent e

133 on of a rare, high-penetrance variant in the complement factor H (CFH) gene that is also causally ass

134 Polymorphisms in the complement factor H (CFH) gene that reduce activity of C

135 A Tyr402His variant in exon 9 in the complement factor H (CFH) gene was also significantly as

136 A locus on chromosome 1q31.1 containing the complement factor H (CFH) gene was strongly associated w

137 inly been attributed to a risk allele in the complement factor H (CFH) gene.

138 ted maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH) genotypes, and other factors,

139 Complement factor H (CFH) has recently been identified a

140 gh interaction with an SNP (rs380390) in the complement factor H (CFH) intron reported to be highly a

141 Complement factor H (CFH) is a central regulator of the

142 Complement factor H (CFH) is a component of the mammalia

143 Complement factor H (Cfh) is a key plasma protein in hum

144 Complement factor H (CfH) is a key regulator of the alte

145 Complement factor H (Cfh) is a key regulator of the alte

146 Complement factor H (CFH) is a major susceptibility gene

147 Complement factor H (CFH) is a negative regulator of the

148 Plasma complement factor H (Cfh) is a potent complement regulat

149 Complement factor H (CFH) is an important regulatory pro

150 Y402H and I62V substitutions in the gene for complement factor H (CFH) is strongly associated with ri

151 associated loci and 6 additional SNPs at the complement factor H (CFH) locus.

152 eptor 1 (CR1) on human erythrocytes (Es) and complement factor H (CFH) on rodent platelets perform im

153 This activation is efficiently suppressed by complement factor H (CFH) on self-surfaces but not on fo

154 smoking, and presence of risk alleles of the complement factor H (CFH) or age-related maculopathy sus

155 plicated in the disease pathology, including complement factor H (CFH) precursor and alpha-2-macroglo

156 Complement factor H (CFH) regulates complement activatio

157 erage of 10.1 years, individuals with 1 or 2 complement factor H (CFH) risk alleles derived maximum b

158 hyperopia, and AMD-susceptibility genotypes Complement Factor H (CFH) RS1061170 and Age Related Macu

159 Two loci in complement factor H (CFH) were included in a risk score

160 have associated a common variant (Y402H) of complement factor H (CFH) with a highly significant incr

161 tomegalovirus (CMV) immunoglobulin (Ig)G and complement factor H (CFH) Y402H genotype.

162 These include complement factor H (CFH), a negative regulator of C3 ac

163 t form of HUS maps to chromosome 1q and that complement factor H (CFH), a regulatory component of the

164 Ten genetic loci in 7 genes [complement factor H (CFH), age-related maculopathy susce

165 mplementary to the 3'-untranslated region of complement factor H (CFH), an important repressor of the

166 y complement fluid-phase regulatory protein, complement factor H (CFH), are strongly associated with

167 Genetic variants of complement factor H (CFH), C3, C2, and FB associated wit

168 ilies were filtered for rare variants in the complement factor H (CFH), complement factor I (CFI), co

169 Genetic variation across the genes encoding complement factor H (CFH), factor B (CFB) and component

170 with the physiological complement inhibitor, complement factor H (CFH), for ligand binding.

171 sm, encoding the sequence variation Y402H in complement factor H (CFH), has been strongly associated

172 Variants of the CFH gene, encoding complement factor H (CFH), show strong association with

173 Two common variants in the gene encoding complement factor H (CFH), the Y402H substitution (rs106

174 that binds the negative complement regulator complement factor H (CFH), thereby inhibiting the altern

175 ponses by hijacking a host-immune regulator, complement factor H (CFH), to the bacterial surface.

176 ly it to a comparison of hemopexin (HPX) and complement factor H (CFH), two liver-secreted glycoprote

177 Complement factor H (CFH), which inhibits complement act

178 ificant peak was found on chromosome 1, near complement factor H (CFH), with P= 6.20 x 10(-4).

179 th age, sex, smoking status, presence of the complement factor H (CFH)-rs1061170 and age-related macu

180 oth common and rare, in the coding region of complement factor H (CFH).

181 omplement proteins or autoantibodies against complement factor H (CFH).

182 ted maculopathy susceptibility 2 (ARMS2) and complement factor H (CFH).

183 ANGPT1) and four retinal genes interact with Complement Factor H (CFH).

184 her [age-related macular degeneration (AMD); complement factor H (CFH)], or even three disease charac

185 Further, we show that complement factor H (FH) binds mCRP to dampen its proinf

186 The ability to recruit complement factor H (FH) by S. pneumoniae has been impli

187 PspC was found to bind human complement factor H (FH) by Western blot analysis of D39

188 plement control protein (CCP) modules within complement factor H (fH) encompass binding sites for C3b

189 iC3b, and C3dg and enhanced competition with complement factor H (FH) in surface plasmon resonance (S

190 Complement factor H (FH) inhibits complement activation

191 Complement factor H (fH) is a plasma protein that regula

192 The complement factor H (FH) mutation R1210C, which was desc

193 Numerous complement factor H (FH) mutations predispose patients t

194 The Tyr402His polymorphism of complement factor H (FH) with 20 short complement regula

195 soluble plasma-regulatory proteins including complement factor H (fH), a 155 kDa protein composed of

196 ement-mediated innate immunity by recruiting complement factor H (FH), a complement alternative pathw

197 Complement factor H (fH), a molecule that downregulates

198 human secretory immunoglobulin A (sIgA) and complement factor H (FH).

199 ve regulator of the AP is the plasma protein complement factor H (FH).

200 Alternative pathway activity is inhibited by complement factor H (FH).

201 und in locus 1q31.3, containing the gene for complement factor H (lead single nucleotide polymorphism

202 is revealed a novel heterozygous mutation in complement factor H (R83S) in addition to known risk pol

203 Interactions with complement factor H (rs1061170), age-related maculopathy

204 Deficiency of complement factor H and mutations in CFH associate with

205 In mice deficient in complement factor H and transgenic for human CR1, solubl

206 d with genetic complement abnormalities/anti-complement factor H antibodies, which paved the way to t

207 Human complement factor H controls spontaneous activation of c

208 ns extend freely into solution when the five complement factor H domains are bound within C3b.

209 MD (P = .03); between rs2669845 and Y402H in complement factor H for AMD (P = .04); and between rs266

210 Polymorphisms in the complement factor H gene (CFH) are associated with a sig

211 typed, an intronic and common variant in the complement factor H gene (CFH) is strongly associated wi

212 actors--smoking and the Y402H variant of the complement factor H gene (CFH)--we used logistic regress

213 a contiguous 358 kb region that contains the Complement Factor H gene cluster.

214 tion studies have found variation within the complement factor H gene family links to host susceptibi

215 Inherited variation in the complement factor H gene is a major risk factor for drus

216 kely caused by the Y402H polymorphism in the complement factor H gene is a recognized risk factor for

217 T-->C substitution in exon 9 (Y402H) of the complement factor H gene is strongly associated with sus

218 age, sex, and the Y402H polymorphism in the complement factor H gene on chromosome 1q) and mortality

219 DNA resequencing of the complement factor H gene within this haplotype revealed

220 Complement factor H genotype had no effect on the respon

221 Deficiency of complement factor H has long been associated with MPGN.

222 work presented here demonstrates that human complement factor H is an adhesion ligand for human neut

223 etic mutation causing aHUS, including 4 with complement factor H mutations.

224 The complement factor H R1210C rare variant confers the stro

225 The typical phenotype of the complement factor H R1210C rare variant is associated wi

226 tients carrying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originat

227 The role of complement factor H still needs to be better defined, bu

228 d, followed by the first five SCR domains of complement factor H that bind to complement C3b.

229 first to a cell surface receptor and then to complement Factor H thereby blocking the lytic activity

230 leukin-6 (IL-6), interleukin-10 (IL-10), and complement factor H was unaffected.

231 Maculopathy Susceptibility 2 rs10490924 and Complement Factor H Y402H (P for trend = 4.2x10(-7)).

232 serine peptidase 1) (P =2.7 x 10(-72)), CFH (complement factor H) (P =2.3 x 10(-47)), C2 (complement

233 We have recently reported that complement factor H, a negative regulator of complement-

234 Indeed, the binding of human complement factor H, a negative regulator of the alterna

235 Genetic investigations have shown that complement factor H, a regulator of the alternative comp

236 Ten loci in 7 AMD genes [complement factor H, age-related maculopathy susceptibil

237 Human complement factor H, consisting of 20 complement control

238 ain, antithrombin III, Fas ligand, factor V, complement factor H, IgK, and Fas.

239 n up to 50% of cases, caused by mutations in complement factor H, membrane cofactor protein, factor I

240 fluid-phase CRP to six immobilized proteins: complement factor H, oxidized low-density lipoprotein, c

241 riants suggest decreased inhibition of C3 by complement factor H, resulting in increased activation o

242 noncoding variant in CFH, the gene encoding complement factor H, that substantially increases the in

243 with these diseases affect the glycoprotein complement factor H, the main regulator of the alternati

244 are disrupted by the abundant serum protein, complement Factor H, thereby probably limiting SIBLING-m

245 characteristic of sub-RPE deposits, such as complement factor H, vitronectin, and amyloid beta, reve

246 a-2-glycoprotein and positively with afamin, complement factor H, VLDL-associated apolipoproteins, an

247 venger receptors, IgM natural antibodies and complement factor H, which bind, neutralize and/or facil

248 association of ARM with the Y402H allele of complement factor H, which has previously been reported

249 e mutant also had decreased binding of human complement Factor H, which in previous studies increased

250 convalescent B1b cell-derived IgM recognizes complement factor H-binding protein (FhbA), a B. hermsii

251 model of MPGN that develops spontaneously in complement factor H-deficient mice (Cfh(-/-)).

252 Copy number variations in the complement factor H-related (CFHR) gene cluster on chrom

253 and identified a chromosomal deletion in the complement factor H-related (CFHR) gene cluster.

254 The autoimmune renal disease deficient for complement factor H-related (CFHR) genes and autoantibod

255 tains the complement factor H (CFH) and five complement factor H-related (CFHR) genes.

256 n includes genomic rearrangements within the complement factor H-related (CFHR) locus.

257 The role of the complement factor H-related (FHR) proteins in homeostasi

258 C3G-associated genomic mutation in the gene complement factor H-related 1 (CFHR1), which encodes FHR

259 onstrates that a duplication within the gene complement factor H-related 1 (CFHR1; encoding FHR1) lea

260 ociation studies have shown that deletion of complement factor H-related genes 1 and 3 (CFHR3,1Delta)

261 e association studies identified deletion of complement factor H-related genes 1 and 3 as protective

262 Human complement factor H-related protein (CFHR) 4 belongs to

263 ing the association of rs7517126 with plasma complement factor H-related protein 1 (CFHR1) level at p

264 , Factor H, Factor H-like protein-1 (FHL-1), complement Factor H-related protein 1 (CFHR1), and plasm

265 and endogenous nitric oxide production) and complement factor H-related protein 2 (CFHR2, related to

266 e cosegregated with the same mutation in the complement factor H-related protein 5 gene (CFHR5).

267 Complement factor H-related proteins (FHRs) are strongly

268 ble proteins, such as C-reactive protein and complement factor H.

269 most common mutation is in the gene encoding complement factor H.

270 02 protein polymorphism in the gene encoding complement factor H.

271 ed, i.e., TSG-6, chemokines IL-8 and KC, and complement factor H.

272 The purified protein was identified as human complement factor H.

273 and OPN form rapid and tight complexes with complement Factor H.

274 the complement cascade C1q, C6, and C8; and complement factor H.

275 Genetic risk factors such as variations in complement factors H (CFH) and B (CFB) have been implica

276 The association of variants in complement factors H and B with age-related macular dege

277 g two host-derived fluid-phase regulators of complement, factor H and factor H-like protein 1 (FHL-1)

278 We demonstrate that complement factor-H related 3 (CFHR3) promotes immune ac

279 e variants in the complement factor H (CFH), complement factor I (CFI), complement C9 (C9), and compl

280 Complement factor I (fI) plays a major role in the regul

281 The linkage of ENPEP to complement factor I (IF) confirms the human chromosome b

282 Both of these proteins act as co-factors for complement factor I (IF).

283 macular degeneration (AMD), we sequenced the complement factor I gene (CFI) in 2266 individuals with

284 C3 convertases; and 4) for susceptibility to complement factor I in the presence of factor H.

285 use model with combined deficiency of FH and complement factor I, CR2-FH prevented de novo C3 deposit

286 Importantly, cell adhesion to the complement factor iC3b is also diminished, and COS cells

287 including members of the ICAM family and the complement factor iC3b.

288 in deficiency led to increased expression of complement factors in muscle, while muscle-specific tran

289 2 diabetic patients revealed the presence of complement factors in the islets and varying degree of c

290 w restriction-induced venous thrombosis that complement factors make distinct contributions to platel

291 n of Igs, pattern recognition molecules, and complement factors on CC in human plasma.

292 e of pathogens and toxins without activating complement factors or coagulation.

293 ls and increased expression of cytokines and complement factors surrounding amyloid deposits.

294 mannose-binding lectin, which are both early complement factors that tag ACs for innate immune recogn

295 iV) include exposure to environments rich in complement factors, we tested the in vitro sensitivity o

296 ibiting drusen proteins and inflammatory and complement factors while upregulating nucleosome, riboso

297 d the deposition of immunoglobulin (Ig)M and complement factors within the xenograft.